General Atlantic’s Royalty Pharma RPRX Stock Holding History

General Atlantic’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,500,000	Closed	-$52.9M	–	16
2025 Q3	$52.9M	Hold	1,500,000	–	–	1.59%	11
2025 Q2	$54M	Hold	1,500,000	–	–	1.49%	11
2025 Q1	$46.7M	Hold	1,500,000	–	–	1.57%	9
2024 Q4	$38.3M	Hold	1,500,000	–	–	1.36%	9
2024 Q3	$42.4M	Hold	1,500,000	–	–	1.21%	11
2024 Q2	$39.6M	Hold	1,500,000	–	–	1.24%	12
2024 Q1	$45.6M	Hold	1,500,000	–	–	1.06%	14
2023 Q4	$42.1M	Hold	1,500,000	–	–	0.6%	16
2023 Q3	$40.7M	Hold	1,500,000	–	–	0.63%	20
2023 Q2	$46.1M	Hold	1,500,000	–	–	0.73%	20
2023 Q1	$54M	Hold	1,500,000	–	–	0.63%	16
2022 Q4	$59.3M	Hold	1,500,000	–	–	0.78%	15
2022 Q3	$60.3M	Hold	1,500,000	–	–	0.71%	16
2022 Q2	$63.1M	Hold	1,500,000	–	–	0.82%	14
2022 Q1	$58.4M	Hold	1,500,000	–	–	0.53%	16
2021 Q4	$59.8M	Hold	1,500,000	–	–	0.46%	17
2021 Q3	$54.2M	Hold	1,500,000	–	–	0.32%	17
2021 Q2	$61.5M	Hold	1,500,000	–	–	0.43%	11
2021 Q1	$65.4M	Hold	1,500,000	–	–	0.77%	8
2020 Q4	$75.1M	Hold	1,500,000	–	–	0.98%	7
2020 Q3	$63.1M	Hold	1,500,000	–	–	0.97%	5
2020 Q2	$72.8M	Buy	+1,500,000	New	+$74.2M	2.18%	4

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

General Atlantic's RPRX Position: Q4 2025 in Review

General Atlantic sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 1,500,000 shares — an estimated $52.9M sold.

General Atlantic first reported a position in RPRX in Q2 2020 and held it in 22 quarters. The position peaked at $75.1M in Q4 2020. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

General Atlantic reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
General Atlantic sold 1,500,000 Royalty Pharma shares in Q4 2025, an estimated $52.9M.
General Atlantic first reported a position in Royalty Pharma in Q2 2020 and held it in 22 quarters.
General Atlantic's Royalty Pharma position peaked at $75.1M in Q4 2020.
539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on General Atlantic's 13F filing for Q4 2025, filed 17 Feb 2026.